173.809 articles found

Disease Duration Differentiates Freezing of Gait Response to Subthalamic and Nigral Stimulation for Parkinson's Disease in an Exploratory Multicenter Controlled Trial

Weiss D, Cebi I, Schütt M, Fischer I, Pavelka L, Kolber P, Pötter‐Nerger M, Hamel W, Kühn A, Hartmann C, Bötzel K, Köglsperger T, Barbe M, Kohl Z, Paschen S, Hobert M, Groppa S, Warnecke T, Claus I, Krüger R, Gharabaghi A.

Movement disorders clinical practice · 2026-10-12

Intrinsically photosensitive retinal ganglion cells: Context-Dependent resilience and vulnerability.

Cella A, Mure LS.

Neurobiology of sleep and circadian rhythms · 2026-10-12

DOI: 10.1016/j.nbscr.2026.100153PMID: 42927207

Targeting the Gut to Modify Parkinson's Disease: From Mechanisms to Potential Therapeutics.

Tai YC, Lin CH.

J Mov Disord · 2026-10-12

DOI: 10.14802/jmd.26285PMID: 42860646

Candidate neurobiological pathways linking physical exercise to cognition in Parkinson's disease: a hypothesis-generating translational framework.

Byun K, Lee JY, Kim R.

J Mov Disord · 2026-10-12

DOI: 10.14802/jmd.26260PMID: 42860647

Disease Duration Differentiates Freezing of Gait Response to Subthalamic and Nigral Stimulation for Parkinson's Disease in an Exploratory Multicenter Controlled Trial.

Weiss D, Cebi I, Schütt M, Fischer I, Pavelka L, Kolber P, Pötter-Nerger M, Hamel W, Kühn AA, Hartmann CJ, Bötzel K, Köglsperger T, Barbe MT, Kohl Z, Paschen S, Hobert MA, Groppa S, Warnecke T, Claus I, Krüger R, Gharabaghi A, Multicenter STN+SNr Study Group.

Mov Disord Clin Pract · 2026-10-12

DOI: 10.1002/mdc3.70813PMID: 42860886

Caregiver Burden and Its Determinants After Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease: A Cross-Sectional Long-Term Follow-Up Study.

Margarido I, Pacheco C, Ramos J, Chamadoira C, Rito M, Oliveira A, Rosas MJ, Ferreira-Pinto MJ, Soares C.

Mov Disord Clin Pract · 2026-10-12

DOI: 10.1002/mdc3.70851PMID: 42860906

Plasma Lipid Remodeling across Preclinical Burden, Disease Onset, and Early Motor Severity in Huntington's Disease.

Bendimerad M, Bonneau D, Scherer-Gagou C, Prundean A, Chikh K, Vitalis O, Olivier A, Blanchet O, Nzoughet-Kouassi J, Verny C, Reynier P, Chao de la Barca JM.

Mov Disord · 2026-10-12

DOI: 10.1002/mds.70531PMID: 42860925

Persistent Therapeutic Burden after Device-Aided Therapy in Parkinson's Disease: Insights from Post-DAT MANAGE-PD Assessment.

Onder H, Gültekin M, Yavuz Z, Çıplaklıgil A, Comoglu S.

Mov Disord Clin Pract · 2026-10-12

DOI: 10.1002/mdc3.70861PMID: 42860929

Target engagement and efficacy in disease-modifying trials of synuclein-related disorders.

Artusi CA, Gallo S, Galli S, Rinaldi D, Tinazzi M, Rascol O, Espay AJ, Fabbri M.

Brain · 2026-10-12

DOI: 10.1093/brain/awag353PMID: 42861702

Gesture-based rehabilitation as an assistive technology for post-infectious and post-critical illness disabilities: opportunities and challenges.

Ali MU, Ghumman UN, Raja MS, Noor E, Ramzan F.

Disabil Rehabil Assist Technol · 2026-10-12

DOI: 10.1080/17483107.2026.2745368PMID: 42861977

The link between inflammation and autonomic dysfunction in alpha-synucleinopathies - narrative review.

Kutyłowski K, Alster P, Madetko-Alster N.

Neurol Neurochir Pol · 2026-10-12

DOI: 10.5603/pjnns.112453PMID: 42861983

Carbon dot-based nanomaterials in neurodegeneration: addressing neurobiological barriers and targeting challenges.

Unnikrishnan B, Anand A, Fang CN, Wu SM, Wang CC, Huang CC, Chu HW, Chang HT.

Chem Commun (Camb) · 2026-10-12

DOI: 10.1039/d6cc03262aPMID: 42862052